Table 2.
Characteristics of allo-HSCT with DLI
| Patients | Day-100 landmark cohort with DLI use | |
|---|---|---|
| preDLI | relDLI | |
| Allo-HSCT [number of patients] | 42 | 51 |
| Graft source: PBHSC fresh / cryopreserved | 40 / 2 | 50 / 1 |
| Donor sex: male / female | 22 / 20 | 30 / 21 |
| Donor age: median (range) | 39 (20–68) | 33 (19–69) |
| Graft cell numbers: median (range) | ||
| WBC × 10−8/kg BW | 10.9 (4.2–22.9) | 9.4 (5.2–29.9) |
| CD3+ cells × 10−6/kg BW | 2.3 (0.1–6.8) | 2.2 (0.1–6.4) |
| CD34+ cells × 10−6/kg BW | 6.9 (2.4–21.0) | 6.5 (1.9–17.0) |
| Post-HSCT GvHD prophylaxis | ||
| CSA/CAMPATH | 25 (60%) | 21 (41%) |
| CSA/MMF or MTX/ ± ATG | 17 (40%) | 30 (59%) |
| GvHD induced by HSCT prior to DLI | ||
| Acute GvHD | 14 (33%) | 22 (43%) |
| Grade: 1 / 2 / 3 / 4 | 11 / 3 / - / - | 10 / 7 / 4 / 1 |
| Chronic GvHD (any grade) | 8 (19%) | 10 (20%) |
| DLI timing and dose regimen | ||
| HSCT to DLI [days]: median (range) | 273 (80–2164) | 191 (63–2172) |
| Stop CSA to DLI [days]: median (range) | 96 (8–1764) | 52 (4–2011) |
| Total number DLI cycles/patient: median (range) | 6 (1–43) | 3 (1–25) |
| n = 1 | 4 (10%) | 9 (18%) |
| n = 2 | 2 (5%) | 11 (22%) |
| n ≥ 3 | 36 (86%) | 31 (61%) |
| CD3+ cell dose [× 10-6/kg BW]: median (range) | ||
| First DLI | 0.69 (0.20–2.27) | 0.84 (0.22–3.56) |
| Second DLI | 0.78 (0.20–2.31) | 1.08 (0.31–4.59) |
| Third or later DLI (highest dose) | 2.31 (0.94–12.51) | 1.80 (0.34–10.02) |
| DLI intervals (≥ 2 cycles) [days]: median (range) | ||
| First to second DLI | 28 (14–1778) | 22 (7–147) |
| First to last DLI | 161 (53–2114) | 65 (8–2472) |
| GvHD following DLI | ||
| Acute GvHD | 12 (29%) | 9 (18%) |
| Grade: 1 / 2 / 3 / 4 | 4 / 5 / - / 3 | 4 / 2 / 3 / - |
| Chronic GvHD (any grade) | 6 (14%) | 5 (10%) |
BW body weight, CSA cyclosporin A, MTX methotrexate, CAMPATH alemtuzumab, MMF mycophenolate mofetil, ATG anti-thymocyte globulin